Notes
Advisory Committee on Immunization Practices
Reference
Cho BH, et al. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions. Vaccine : 19 Oct 2013. Available from: URL: http://dx.doi.org/10.1016/j.vaccine.2013.10.024
Rights and permissions
About this article
Cite this article
PCV13 worth a shot in immunocompromised adults. PharmacoEcon Outcomes News 691, 8 (2013). https://doi.org/10.1007/s40274-013-0867-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0867-7